Howie and Harlan are joined by Tina Loarte-Rodríguez, associate director, health equity measures, at Yale's Center for Outcomes Research & Evaluation and the author of Latinas in Nursing: Stories of Determination, Inspiration, and Trust. And Howie and Harlan discuss the clinical and economic dimensions of two newly approved CRISPR-based treatments for sickle cell disease.
Links:
Tina Loarte-Rodríguez
Tina Loarte-Rodríguez: Latinas in Nursing: Stories of Determination, Inspiration, and Trust
Center for Outcomes Research & Evaluation (CORE)
Center for Outcomes Research & Evaluation: Quality Measurement
"Sociodemographic Disparities in Queue Jumping for Emergency Department Care"
New Treatments for Sickle Cell Disease
"In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease"
"F.D.A. Approves Sickle Cell Treatments, Including One That Uses CRISPR"
The Nobel Prize in Chemistry 2020
Yale New Haven Health: Sickle Cell Program
"Milestones in Sickle Cell Research and Care"
Bluebird Bio
Yahoo Finance: Bluebird Bio, Inc.
"Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy"
"Harlan M. Krumholz Named Next Editor-in-Chief of JACC"
Read an unedited transcript of this episode.
Learn more about the MBA for Executives program at Yale SOM.
Learn more about the Pozen-Commonwealth Fund Fellowship in Health Equity Leadership.
Email Howie and Harlan comments or questions.
